Monitor upcoming clinical trial timelines for BETR-001 and watch for additional capital raises, as the company appears to be actively funding development through equity issuance which could lead to further dilution. The high-profile advisor appointments may improve partnership prospects in the psychedelic medicine space.
Price Chart
Executive Summary
BetterLife Pharma announced a $500,000 private placement, multiple debt conversions, and key personnel changes including the appointment of high-profile advisors Daniel Carcillo and Doug Drysdale. The company also extended convertible debentures and issued shares for services, indicating ongoing capital raising and strategic development for its lead compound BETR-001.
Key Facts
- Announced $500,000 private placement at $0.07 per unit (April 8, 2026)
- Converted $215,320.55 of convertible debentures into 2,153,205 common shares and warrants (April 2, 2026)
- Extended maturity dates of convertible debentures by one year (April 10, 2026)
- Appointed Daniel Carcillo (former NHL player and TBI advocate) and Doug Drysdale (former Cybin CEO) as corporate advisors
- Issued 6,050,000 stock options to directors, officers, and employees (February 23, 2026)
- Two board members (Andr Beaudry and Robert Metcalfe) resigned in late 2025
Financial Impact
Raised $500,000 through private placement and converted $215,320.55 of debt to equity, with significant share dilution from multiple issuances
Risk Factors
- Significant share dilution from multiple share issuances and warrant grants
- Continued reliance on convertible debt financing indicates potential cash flow challenges
- Clinical development timeline for BETR-001 remains uncertain with human trials planned for second half of 2026
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 13 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001477932-26-002155 |
| Document: betrf_6k.htm | 0001477932-26-002155 |
| Document: betrf_ex997.htm | 0001477932-26-002155 |
| Document: betrf_ex995.htm | 0001477932-26-002155 |
| Document: betrf_ex998.htm | 0001477932-26-002155 |
| Document: betrf_ex992.htm | 0001477932-26-002155 |
| Document: betrf_ex996.htm | 0001477932-26-002155 |
| Document: betrf_ex994.htm | 0001477932-26-002155 |
| Document: betrf_ex993.htm | 0001477932-26-002155 |
| Document: betrf_ex991.htm | 0001477932-26-002155 |
| Document: 0001477932-26-002155-index-headers.html | 0001477932-26-002155 |
| Document: 0001477932-26-002155-index.html | 0001477932-26-002155 |
| Document: 0001477932-26-002155.txt | 0001477932-26-002155 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 29, 2026 26d ago | 6-K | $0.2410 $0.1920 | ▼ −20.33% | ▼ −22.25% | $0.1685 (−30.08%) |
Sep 22, 2026 4w ago | SC 13G | $0.2400 $0.2410 | ▲ +0.42% | ▲ +1.09% | $0.1685 (−29.79%) |
Sep 15, 2026 5w ago | 6-K | $0.2740 $0.2217 | ▼ −19.09% | ▼ −19.91% | $0.1685 (−38.50%) |
Sep 11, 2026 6w ago | 6-K | $0.2300 $0.2550 | ▲ +10.87% | ▲ +11.09% | $0.1685 (−26.74%) |
Aug 24, 2026 9w ago | 6-K | $0.2240 $0.2195 | ▼ −2.01% | ▼ −2.48% | $0.1685 (−24.78%) |
Jun 26, 2026 17w ago | 6-K | $0.1110 $0.1310 | ▲ +18.02% | ▲ +15.85% | $0.1685 (+51.80%) |
Apr 13, 2026 27w ago | 6-K | $0.0410 $0.0480 | ▲ +17.07% | ▲ +13.78% | $0.1685 (+310.98%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers